Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24331778 | 0.85 | DRD2 (0.43) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL23781493 | 0.85 | CASP1 (0.44) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL23781494 | 0.85 | CASP1 (0.44) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL18005631 | 0.82 | HTR1A (0.40) | ALDH1A1HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL9488089 | 0.81 | CETP (0.50) | ALDH1A1HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL18005335 | 0.81 | HTR1A (0.40) | ALDH1A1HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL18029842 | 0.81 | HTR1A (0.40) | ALDH1A1HTR1ADRD2HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL8580756 | 0.80 | CETP (0.49) | ALDH1A1HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL18005647 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL19899742 | 0.77 | PDE10A (0.44) | HTR1ADRD2HTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719006-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3719006-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3719006-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | Arizona Board of Regents on behalf of Arizona State University (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719006-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | Arizona Board of Regents on behalf of Arizona State University (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3259254-B1 | DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3259254-B1 | DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10364227-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-10364227-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180319751-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2016133959-A9 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2016133959-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319751-A1 | THERAPEUTIC COMPOUNDS | SDHA, CYP11B1, CYP11B2 | ALDH1A1 176/4885HTR1A 2578/4885DRD2 2791/4885 |
| US-10364227-B2 | Therapeutic compounds | SDHA, CYP11B1, CYP11B2 | ALDH1A1 176/4885HTR1A 2578/4885DRD2 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.